Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties.
about
The retinal determination gene network: from developmental regulator to cancer therapeutic targetBreast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticityStructure-function analyses of the human SIX1–EYA2 complex reveal insights into metastasis and BOR syndromeInterplay of retinal determination gene network with TGF-β signaling pathway in epithelial-mesenchymal transitionThe EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromaroneStructure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agentsAllosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells.A phosphotyrosine switch determines the antitumor activity of ERβ.EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells.Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progressionCyclic AMP enhances TGFβ responses of breast cancer cells by upregulating TGFβ receptor I expression.The PI3K/Akt signal hyperactivates Eya1 via the SUMOylation pathway.The SIX1-EYA transcriptional complex as a therapeutic target in cancer.Drosophila eyes absent is a novel mRNA target of the tristetraprolin (TTP) protein DTIS11The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer.Gene expression in "young adult type" breast cancer: a retrospective analysis.The Eyes Absent proteins in development and disease.Six1 induces protein synthesis signaling expression in duck myoblasts mainly via up-regulation of mTORThe phosphatase-transcription activator EYA1 is targeted by anaphase-promoting complex/Cdh1 for degradation at M-to-G1 transition.The relevance of the TGF-β Paradox to EMT-MET programsEYA1 phosphatase function is essential to drive breast cancer cell proliferation through cyclin D1.CDK6 binds and promotes the degradation of the EYA2 proteinCancer driver-passenger distinction via sporadic human and dog cancer comparison: a proof-of-principle study with colorectal cancer.SIX1 maintains tumor basal cells via transforming growth factor-β pathway and associates with poor prognosis in esophageal cancer.Atypical protein phosphatases: emerging players in cellular signaling.Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2.The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis.Eya2, a Target Activated by Plzf, Is Critical for PLZF-RARA-Induced Leukemogenesis.Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.The canonical wnt signal restricts the glycogen synthase kinase 3/fbw7-dependent ubiquitination and degradation of eya1 phosphatase.The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes.Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth.EYA1 expression and subcellular localization in neuroblastoma and its association with prognostic markersEya2 overexpression promotes the invasion of human astrocytoma through the regulation of ERK/MMP9 signaling.The Eya phosphatase: Its unique role in cancer.EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN.The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.
P2860
Q26747218-3C51DE81-343B-47CB-85EA-04BB19621783Q26851620-FD2304D7-8664-4B9E-A47E-150D6457BC70Q27676610-BDD3A3B4-5E16-4037-9215-43C8B6222B4CQ28088611-89180318-B567-4605-B8F3-1A197587259BQ28482486-554D3759-42CF-4CF6-97C1-4C2CC82DDCE0Q28537736-E83E489F-D708-4577-9BE7-C0D4184CCB94Q30409822-71395370-534A-47D9-A03D-3B17D86370EAQ33804808-0A46F9B5-3942-4CBD-B8A4-89F36EC5632EQ33944154-BB92AEFD-7820-4A41-979C-215162C2B421Q34283431-D80D3593-3808-4E1C-9E24-2A9D4E2FD3B0Q34347238-2FEA1676-2A27-4585-8A77-63B148077D4BQ34374689-FDD5EA95-8A59-4D86-97D1-F8EBD4D70FD7Q34516160-7D511E18-9E3D-4C89-86EB-C8CE69D178B8Q34562845-4F187A15-468E-414B-8B20-20BB17C87DE2Q34766011-59D1FC4E-8F76-4F4C-B652-1E91D41A4028Q35107900-998CCC67-A71C-44E5-AA1E-1E7BF17F7BF8Q35926324-F6BD855C-3D70-40A5-A1E9-1A8E8486C0EAQ35928749-34A1005A-87FA-406F-869C-873FE1C957C7Q35955416-6CC0332D-00A6-4665-B515-4A17FFD42FFAQ36597900-95FF3429-DB6E-4D00-B728-84AE05039B6DQ36727713-5C1664AF-D859-484A-8CD7-2FE19BA57428Q36757059-A3EF7453-6ED0-464A-9EB8-EF0DDF3B8636Q37118399-C88D3627-3679-49F3-8C1D-F854BE59D08DQ37128230-16B3A114-2E7D-48FB-A432-79BD336F630AQ37587030-61E8A713-3652-4400-AE87-860784A52CC0Q37598464-3D7685B3-91C8-4356-99D2-D7D0704B2EB1Q37670690-C331165C-62A3-4232-A7CB-5F272FC16C60Q38084832-AE3D8D49-BD64-49ED-AB16-F61B1445D7CDQ38537769-EFC786D3-C007-475C-AA04-161540B3A767Q38681168-926E33F8-7E52-48E2-A57A-ED89EB2C0C67Q38833595-9EB5C747-7037-445B-9188-32EE200ED078Q38963936-24779EE1-0CE5-4F3D-8C1F-097F23C3DF5DQ39002239-4A7FC9D9-E037-4A11-81C3-17A515EEA9CCQ40394481-642C981D-129B-4A09-BCA0-8ECAB5B1F9C3Q40720870-4A6F4686-9EC2-4C8B-9FEB-8DD7A0DBC3B5Q40993139-E5A6200D-BE66-4CDE-B1A3-352C64793612Q42280231-E4E9162B-5548-448B-A0E6-FD6354476CF0Q47832015-F364FAB5-ACBA-4C86-8D1A-79FFE5E5C3BCQ49497954-C67BEC6F-0D92-43BB-9DAC-783C9B4858D5Q52584557-802330F4-A92B-40E0-BD6E-4444652B3E6D
P2860
Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Eya2 is required to mediate th ...... d cancer stem cell properties.
@ast
Eya2 is required to mediate th ...... d cancer stem cell properties.
@en
type
label
Eya2 is required to mediate th ...... d cancer stem cell properties.
@ast
Eya2 is required to mediate th ...... d cancer stem cell properties.
@en
prefLabel
Eya2 is required to mediate th ...... d cancer stem cell properties.
@ast
Eya2 is required to mediate th ...... d cancer stem cell properties.
@en
P2093
P2860
P356
P1433
P1476
Eya2 is required to mediate th ...... d cancer stem cell properties.
@en
P2093
D S Micalizzi
P Jedlicka
S M Farabaugh
P2860
P2888
P304
P356
10.1038/ONC.2011.259
P407
P577
2011-06-27T00:00:00Z